Pure Global
NCT06305663

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Bausch & Lomb Incorporated·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Myopia
Drug/Device/Intervention
Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Bausch & Lomb Incorporated
Location
Beijing,Dongcheng,Xiamen,Haikou,Wuhan,Shanghai,Taiyuan,Shenzhen,Chengdu,Nankai,Wenzhou, China
Timeline & enrollment
Phase
N/A
Start date
Mar 29, 2024
End date
Jan 31, 2027
Enrollment
418 participants
Primary outcome

Mean change from baseline in axial length.,Mean change from baseline in cycloplegic SERE.

Summary

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the
 Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

ICD-10 classifications
MyopiaDegenerative myopiaAmblyopia ex anopsiaOcular myiasisMyiasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06305663
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06305663 through Pure Global AI's free database. This phase not specified trial is sponsored by Bausch & Lomb Incorporated and is currently Not yet recruiting. The study focuses on Myopia. Target enrollment is 418 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.